Chemo–immunotherapy with cisplatin and nivolumab as second-line approach in metastatic adrenocortical carcinoma
Authors' conclusion
The combination of cisplatin and nivolumab is an active regimen in advanced, previously treated, ACC patients. The long survival achieved in this patient population with a poor prognosis is promising.
Study context
- Population
- Advanced/metastatic adrenocortical carcinoma (ACC) with disease progression to EDP-M regimen plus/minus other chemotherapeutic regimens
- Participants
- 23 participants
- Outcome
- Disease response according to RECIST
Methodological detailssingle-arm, Enrolled between January 2023 and March 2025
- Single-arm
- Enrolled between January 2023 and March 2025
Main finding
As reported in the abstract
Disease response (RECIST)
Partial response
8 patients [34.8% (95% CI, 15.3%-54.2%)]
Stable disease
4 patients
17.3%
Observational data: associations, not effects.
Secondary outcomes
Clinical benefit
- Clinical benefit
- 12 patients (52.2%)
Disease control rate (DCR) · 6 months
- DCR
- 39.1% [95% CI, 19.7%-61.5%]
Progression-free survival (PFS)
- Median PFS
- 4.3 months [95% CI, 3.9-13.0]
Overall survival (OS) · median follow-up 15.1 months
- Median OS
- 18.9 months [95% CI, 15.8-not reached]
Safety
Toxicity
- Discontinued after 1 cycle due to grade 3 immune-related hepatitis
- 1 patient
- Well tolerated; most toxicities limited to grade G1-2 (National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE))
Original publication
Chemo–immunotherapy with cisplatin and nivolumab as second-line approach in metastatic adrenocortical carcinoma. Eur J Endocrinol. Published 14 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →